D

Daniel D. Von Hoff

Translational Genomics Research Institute

ORCID: 0000-0003-4723-7681

1.5k papers and 70.9k citations.

PubIndex Score98Top 2%How it's scored

1.5kPublications

70.9kTotal Citations

First publication: 1974First senior author: 1978

Top publicationsby citations

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Markus F. Renschler, Jeffrey R. Infante et al.|New England Journal of Medicine|2013

Cited by 6.6k

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Daniel D. Von Hoff, Malcolm J. Moore et al.|Journal of Clinical Oncology|1997

Cited by 5.9k

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Mace L. Rothenberg, Daniel D. Von Hoff, Malcolm J. Moore et al.|Annals of Oncology|1996

Cited by 569

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Mark Sausen, Victor E. Velculescu, Jillian Phallen et al.|Nature Communications|2015

Cited by 484

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

Joyce O’Shaughnessy, Daniel D. Von Hoff, Gary J. Kelloff et al.|PubMed|2002

Cited by 383

Indexing the rest of 1,530 publications…